Table 1.
Population demographics and baseline characteristics
| Demographics | |
| Male | 13 (76%) |
| Female | 4 (24%) |
| Median age (range), years | 66 (58 – 73) |
| Asian | 2 (12%) |
| Caucasian | 10 (59%) |
| Hispanic | 4 (24%) |
| Other | 1 (6%) |
| Liver disease etiologies | |
| Alcohol | 3 (18%) |
| HCV | 3 (18%) |
| HCV and alcohol | 5 (29%) |
| Non-alcoholic fatty liver disease | 3 (18%) |
| HBV | 1 (6%) |
| Primary sclerosing cholangitis | 1 (6%) |
| Cryptogenic | 1 (6%) |
| Baseline liver function | |
| Median MELD-Na score (range) | 12 (7 – 26) |
| Median CPT score (range) | 10 (6 – 12) |
| Child Pugh class A / B / C | 1 / 7 / 9 |
| ALBI score grade 1 / 2 / 3 | 1 / 8 / 8 |
| Liver Dysfunction Categories for Inclusion | |
| Symptomatic ascites | 14 (82%) |
| Serum bilirubin 3-6 mg/dl | 5 (29%) |
| AST > 5 times upper normal limit | 1 (6%) |
| INR 1.6-2.5 [not on anticoagulation] | 4 (24%) |
| Main portal vein thrombosis | 1 (6%) |
| Patent TIPS | 1 (6%) |
| Patent surgical splenorenal shunt | 1 (6%) |
| ECOG performance status | |
| 0 / 1 / 2 | 7 (41%) / 9 (53%) / 1 (6%) |
| Tumor Burden | |
| Median lesion size (range), cm | 3.0 (1.1 – 6.5) |
| Number of lesions per patient: 1 / 2 / 3 / 4 | 14 / 2 / 0 / 1 |
| Within Milan | 12 (70%) |
| Outside Milan, but within UCSF Downstaging | 3 (18%) |
| Outside UCSF Downstaging | 2 (12%) |
| BCLC stage A / B / C / D | 0 / 5 (29%) / 3 (18%) / 9 (53%) |
| Prior therapy (patients) | |
| No prior interventions | 10 (59%) |
| cTACE | 5 (29%) |
| DEB-TACE | 7 (41%) |
| RFA | 3 (18%) |
| AFP median (range), ng/ml | 22 (6-1191) |
| < 20 | 8 (47%) |
| 20 – 200 | 4 (24%) |
| > 200 | 5 (29%) |
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; MELD-Na, model for end-stage liver disease with sodium; CPT, Child-Pugh-Turcotte; AST, aspartate aminotransferase; INR, international normalized ratio for prothrombin time; TIPS, transjugular intrahepatic portosystemic shunt; ECOG, Eastern Cooperative Oncology Group; UNOS, United Network for Organ Sharing; BCLC, Barcelona Clinic Liver Cancer; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug eluting bead transarterial chemoembolization; RFA, radiofrequency ablation; AFP, alpha fetoprotein.